Applying the New Guidelines of HER2 Testing in Breast Cancer.

Zhang, Huina; Moisini, Ioana; Ajabnoor, Rana M; Turner, Bradley M; Hicks, David G

Zhang, Huina; Moisini, Ioana; Ajabnoor, Rana M; Turner, Bradley M; Hicks, David G.

Afiliação

Zhang H; Department of Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Moisini I; Department of Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Ajabnoor RM; Department of Pathology, Faculty of medicine, King Abdulaziz University, Jeddah, 21589, Kingdom of Saudi Arabia.
Turner BM; Department of Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Hicks DG; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642, USA. David_Hicks@URMC.Rochester.edu.

Curr Oncol Rep ; 22(5): 51, 2020 04 29.

Article em En | MEDLINE | ID: mdl-32346807

Assuntos

Neoplasias da Mama/química; Receptor ErbB-2/análise; Osso e Ossos/química; Feminino; Humanos; Guias de Prática Clínica como Assunto

Palavras-chave

ASCO/CAP guideline; Breast cancer; HER2; Testing

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google